Metis Global Partners’s Bristol-Myers Squibb BMY Stock Holding History

Metis Global Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.55M	Sell	61,550 -32,454	-35%	-$1.86M	0.08%	199
2026 Q1	$5.7M	Sell	94,004 -6,591	-7%	-$384K	0.14%	119
2025 Q4	$5.43M	Sell	100,595 -7,145	-7%	-$344K	0.13%	133
2025 Q3	$4.86M	Sell	107,740 -7,866	-7%	-$367K	0.11%	155
2025 Q2	$5.35M	Sell	115,606 -7,119	-6%	-$349K	0.14%	135
2025 Q1	$7.48M	Buy	122,725 +16,222	+15%	+$946K	0.21%	85
2024 Q4	$6.02M	Buy	106,503 +5,859	+6%	+$327K	0.18%	91
2024 Q3	$5.21M	Buy	100,644 +4,687	+5%	+$220K	0.16%	109
2024 Q2	$3.99M	Sell	95,957 -21,043	-18%	-$942K	0.14%	124
2024 Q1	$6.34M	Sell	117,000 -2,251	-2%	-$115K	0.23%	69
2023 Q4	$6.12M	Buy	119,251 +17,479	+17%	+$918K	0.24%	64
2023 Q3	$5.91M	Buy	101,772 +13,122	+15%	+$804K	0.29%	61
2023 Q2	$5.67M	Sell	88,650 -496	-0.6%	-$33.3K	0.31%	56
2023 Q1	$6.18M	Buy	89,146 +22,128	+33%	+$1.56M	0.4%	48
2022 Q4	$4.82M	Buy	67,018 +28,364	+73%	+$2.14M	0.43%	45
2022 Q3	$2.75M	Buy	38,654 +1,846	+5%	+$134K	0.44%	42
2022 Q2	$2.83M	Buy	36,808 +1,839	+5%	+$140K	0.45%	42
2022 Q1	$2.55M	Buy	34,969 +15,607	+81%	+$1.05M	0.31%	62
2021 Q4	$1.21M	Buy	+19,362	New	+$1.14M	0.34%	65

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Metis Global Partners's BMY Position: Q2 2026 in Review

Metis Global Partners reduced its Bristol-Myers Squibb (BMY) stake by 35% in Q2 2026, selling an estimated $1.86M and leaving 61,550 shares worth $3.55M. The position accounts for 0.08% of the portfolio, ranked #199.

Metis Global Partners first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $7.48M in Q1 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Metis Global Partners held 61,550 shares of Bristol-Myers Squibb worth $3.55M as of Q2 2026.
Metis Global Partners sold 32,454 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.86M.
Bristol-Myers Squibb made up 0.08% of Metis Global Partners's portfolio in Q2 2026, its #199 holding.
Metis Global Partners first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
Metis Global Partners's Bristol-Myers Squibb position peaked at $7.48M in Q1 2025.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Metis Global Partners's 13F filing for Q2 2026, filed 10 Aug 2026.